Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer

• Publication date

  2008-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.23812PMID 18780317PMCID PMC9094399
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data.

  2009cited by this paper
• Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.

  2007cited by this paper
• Preoperative management of the pheochromocytoma patient.

  2007cited by this paper
• High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing.

  2006cited by this paper
• Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.

  2006cited by this paper
• Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

  2006cited by this paper
• The effects in mice of combined treatments to X-rays and antineoplastic drugs in the Comet assay.

  2005cited by this paper
• Pheochromocytoma and functional paraganglioma

  2005cited by this paper
• Pheochromocytoma: state-of-the-art and future prospects.

  2005cited by this paper
• Genetic testing in pheochromocytoma or functional paraganglioma.

  2005cited by this paper
• Phaeochromocytoma.

  2005cited by this paper
• Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas.

  2005cited by this paper
• Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil

  2004cited by this paper
• Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

  2004cited by this paper
• Malignant pheochromocytoma: current status and initiatives for future progress.

  2004cited by this paper
• Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline.

  2003cited by this paper
• Adrenal incidentaloma

  2003cited by this paper
• Pheochromocytoma: state-of-the-art and future prospects.

  2003cited by this paper
• The management of benign and malignant pheochromocytoma and abdominal paraganglioma.

  2003cited by this paper
• Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.

  2003cited by this paper
• Sabiston. Textbook of Surgery: The Biological Basis of Modern Surgical Practice

  2002cited by this paper
• Clinical differences between benign and malignant pheochromocytomas.

  2001cited by this paper
• Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma

  2001cited by this paper
• Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center.

  2001cited by this paper
• Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice

  2001cited by this paper
• Adrenal incidentaloma.

  2000cited by this paper
• Perianesthetic Risks and Outcomes of Pheochromocytoma and Paraganglioma Resection

  2000cited by this paper
• Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma.

  2000cited by this paper
• Clinical experience over 48 years with pheochromocytoma.

  1999cited by this paper
• Pheochromocytomas: can malignant potential be predicted?

  1999cited by this paper
• Pheochromocytoma in Italy: a multicentric retrospective study.

  1999cited by this paper
• A malignant primary cardiac pheochromocytoma.

  1999cited by this paper
• In vitro evaluation of temozolomide combined with X-irradiation

  1997cited by this paper
• Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.

  1997cited by this paper
• Cross resistance and collateral sensitivity between cytotoxic drugs and radiation in two human bladder cell lines.

  1996cited by this paper
• Clinical Spectrum and Outcome of Functional Extraadrenal Paraganglioma

  1996cited by this paper
• Spells: in search of a cause.

  1995cited by this paper
• Incidence of pheochromocytoma in South Galicia, Spain

  1994cited by this paper
• Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

  1994cited by this paper
• Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases

  1992cited by this paper
• A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience.

  1991cited by this paper
• Pheochromocytoma: new concepts and future trends.

  1991cited by this paper
• Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.

  1988cited by this paper
• The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981.

  1988cited by this paper
• Production of the α Subunit of Guanine Nucleotide-binding Protein Go by Neuroendocrine Tumors

  1987cited by this paper
• Production of the alpha subunit of guanine nucleotide-binding protein GO by neuroendocrine tumors.

  1987cited by this paper
• Malignant phaeochromocytoma.

  1985cited by this paper
• Phaeochromocytoma in Queensland--1970-83.

  1985cited by this paper
• Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.

  1983cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• Pheochromocytoma: current status and changing trends.

  1982cited by this paper
• Clinical experience with malignant pheochromocytomas.

  1982cited by this paper
• CURRENT MANAGEMENT OF PHEOCHROMOCYTOMA

  1975cited by this paper
• Current Management of Pheochromocytoma

  1974cited by this paper
• The catecholamines in tumor and urine from patients with neuroblastoma, ganglioneuroblastoma and pheochromocytoma.

  1968cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• PHÆOCHROMOCYTOMA

  1954cited by this paper

• Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review

  2026cites this paper
• Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025

  2025cites this paper
• Chemoradiotherapy for recurrent CBTs case report

  2025cites this paper
• Pheochromocytoma in MEN2.

  2025cites this paper
• Bone metastases in pheochromocytomas and paragangliomas: a narrative review of presentation, diagnosis and management

  2025cites this paper
• Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma.

  2025cites this paper
• Photodegradation of dacarbazine irradiated by common lighting sources: An examination of the differences between light-emitting diode (LED) and fluorescent light.

  2025cites this paper
• Approach to the Patient with Metastatic Pheochromocytoma and Paraganglioma.

  2025cites this paper
• European clinical guidance for the management of adrenal and extra-adrenal paraganglioma in children and adolescents: a consensus by the EXPeRT group.

  2025cites this paper
• Succinate Dehydrogenase-Deficient Cancer Cells Have Increased Susceptibility to Ym155 Induced DNA Damage

  2025cites this paper
• Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy

  2025cites this paper
• Update on Systemic Therapies for Metastatic/Unresectable Pheochromocytomas and Paragangliomas and Future Directions

  2025cites this paper
• Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma

  2024cites this paper
• International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents

  2024cites this paper
• Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.

  2024cites this paper
• Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data

  2024cites this paper
• Constructing a Novel Amino Acid Metabolism Signature: A New Perspective on Pheochromocytoma Diagnosis, Immune Landscape, and Immunotherapy

  2024cites this paper
• Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice.

  2024cites this paper
• Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid

  2024cites this paper
• The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives

  2024cites this paper
• Molecular Genetics of Pheochromocytoma/Paraganglioma.

  2024cites this paper
• Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol

  2024cites this paper
• Current views on paediatric phaeochromocytoma and paraganglioma with a focus on newest guidelines.

  2024cites this paper
• Treatment of metastatic pheochromocytoma and paraganglioma

  2024cites this paper
• Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options

  2023cites this paper
• [French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network].

  2023cites this paper
• Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement

  2023cites this paper
• Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas

  2023cites this paper
• A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide

  2023cites this paper
• Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade

  2023cites this paper
• Metastatic paraganglioma presenting with spinal cord compression requiring urgent surgery

  2023cites this paper
• Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.

  2023cites this paper
• Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.

  2023cites this paper
• A case of neck paraganglioma in a 49-year-old male: Case report and review of the literature

  2023cites this paper
• Paraganglioma of the head and neck: A Review.

  2022cites this paper
• The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review

  2022cites this paper
• Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic pheochromocytomas/paragangliomas：A systematic review and meta-analysis.

  2022cites this paper
• Management of a Composite Pheochromocytoma (Pheochromocytoma/Neuroblastoma) in Adult Patient Recurring After Several Years: A Complex Case Report

  2022cites this paper
• Retroperitoneal Paraganglioma often Atypical: Short Case Series and Review of the Literature

  2022cites this paper
• Metastatic sporadic paraganglioma with EWSR1::CREM gene fusion: A unique molecular profile that expands the phenotypic diversity of the molecular landscape of the EWSR1::CREM gene fusion positive tumors

  2022cites this paper
• Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance

  2022cites this paper
• New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications

  2022cites this paper
• Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas

  2022cites this paper
• SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.

  2022cites this paper
• New biology of pheochromocytoma and paraganglioma.

  2022cites this paper
• Personalized Management of Pheochromocytoma and Paraganglioma

  2021cites this paper
• MicroRNAs, Long Non-Coding RNAs, and Circular RNAs: Potential Biomarkers and Therapeutic Targets in Pheochromocytoma/Paraganglioma

  2021cites this paper
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma

  2021cites this paper
• Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog

  2021cites this paper
• Metastatic Pheochromocytomas and Abdominal Paragangliomas

  2021cites this paper
• Successful Response to Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy in a Patient with Metastatic Carotid Body Paraganglioma

  2021cites this paper
• Functional Malignant Retroperitoneal Paraganglioma with Liver Metastasis: a Rare Case Report

  2021cites this paper
• Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study

  2021cites this paper
• Paragangliomas laterocervicales

  2021cites this paper
• Model systems in SDHx-related pheochromocytoma/paraganglioma

  2021cites this paper
• Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.

  2021cites this paper
• Antiproliferative effects of metformin in cellular models of pheochromocytoma.

  2021cites this paper
• Management of Cardiac Paragangliomas

  2021cites this paper
• Late diagnosis of metastatic pheochromocytoma in multiple endocrine neoplasia 2B with rapid clinical decline

  2021cites this paper
• Familial SDHB gene mutation in disseminated non-hypoxia-related malignant paraganglioma treated with [90Y]Y/[177Lu]Lu- DOTATATE.

  2021cites this paper
• Contemporary management of paragangliomas of the head and neck

  2021cites this paper
• Rare Diseases of the Oral Cavity, Neck, and Pharynx

  2021cites this paper
• Cancer of the Endocrine System

  2020cites this paper
• Paragangliomes latéro-cervicaux

  2020cites this paper
• Recent advances in the management of pheochromocytoma and paraganglioma

  2020cites this paper
• Metastasiertes

  2020cites this paper
• A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature

  2020cites this paper
• Recurrent Primary Intrasellar Paraganglioma

  2020cites this paper
• Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma

  2020cites this paper
• Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma

  2020cites this paper
• Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid

  2020cites this paper
• Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on endocrine hypertension of the European society of hypertension.

  2020cites this paper
• Paragangliomi laterocervicali

  2020cites this paper
• Metastatic paraganglioma

  2020cites this paper
• A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation

  2019cites this paper
• Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE

  2019cites this paper
• Paragangliomas in Carney–Stratakis Syndrome

  2019cites this paper
• Characterization of Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades.

  2019cites this paper
• Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.

  2019cites this paper
• Clinical implications of the oncometabolite succinate in SDHx‐mutation carriers

  2019cites this paper
• Progress in the diagnosis and treatment of paraganglioma

  2019cites this paper
• A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial

  2019cites this paper
• Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies

  2019cites this paper
• Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine

  2019cites this paper
• OTT_A_219056 7227..7241

  2019cites this paper
• Therapies targeting the signal pathways of pheochromocytoma and paraganglioma

  2019cites this paper
• Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma

  2019cites this paper
• Orbital Pheochromocytoma Metastasis in 2 Patients With Known Pheochromocytoma.

  2019cites this paper
• Medical Management of Pheochromocytoma

  2018cites this paper
• Rectal Paraganglioma

  2018cites this paper
• Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management

  2018cites this paper
• Case - Bladder paraganglioma in a pediatric patient.

  2018cites this paper
• Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer

  2018cites this paper
• [A CASE OF MALIGNANT PARAGANGLIOMA OF THE URINARY BLADDER TREATED WITH CYCLOPHOSPHAMIDE, VINCRISTINE, AND DACARBAZINE CHEMOTHERAPY AND METAIODOBENZYLGUANIDINE THERAPY].

  2018cites this paper
• Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature

  2018cites this paper
• Surgical Versus Nonsurgical Management of Malignant Pheochromocytoma

  2018cites this paper
• Targeting NAD+/PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma

  2018cites this paper
• Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options

  2018cites this paper
• Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy

  2018cites this paper
• Metastatic pheochromocytoma in MEN 2A: A rare association

  2018cites this paper